HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Aspirin Tackles Cardiovascular Risks In ‘Official Sponsor Of Fans’ Hearts’ Campaign

Executive Summary

It’s airing campaign ads during regional NBC Sports broadcasts and nationally on FOX, ESPN, ESPN2 and NBA TV starting 6 February. While Super Bowl annually is among most watched TV programs worldwide, Bayer notes in 2021 around 57.5m US viewers watched digital live sports at least once a month.

You may also be interested in...



‘Faster, Better, More Efficient’ – Why Bayer Is Investing In ‘Precision Health’

Bayer's head of R&D and chief scientific officer David Evendon-Challis talked to Medtech Insight about the company's prescision health business, including a holistic and personalized approach to digital self-care.

‘Faster, Better, More Efficient’ – Why Bayer Is Investing In ‘Precision Health’

Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care. In the first part of an exclusive interview, HBW Insight catches up with the company's head of R&D and chief scientific officer David Evendon-Challis to dig deeper into the rationale for setting up a new 'prescision health' business unit, including why a holistic and personalized approach to digital self-care increases trust in long-loved and science-backed brands. 

Bayer Wants Aspirin CVD Screening Tool To Reach 100m In US As It Plans International Roll-Out

Bayer hopes its innovative Aspirin-branded Heart Risk Assessment Tool will reach 100m in the US and its planning an international roll-out, the firm's general manager and vice president of pain and cardio, US, Kelly Fanning tells HBW Insight in an exclusive Q&A. Fanning also explains what Bayer is doing to manage the current surge in demand for Aspirin in the US, UK and Europe.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel